Document Detail


Somatostatin in the treatment of patients with extra-pyramidal disorders and patients with EEG abnormalities.
MedLine Citation:
PMID:  151476     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The growth hormone release inhibiting hormone acts probably both as a true hypophysiotropic hormone and as a neuroregulatory substance. Neurophysiological studies have shown that somatostatin is a CNS depressant. Somatostatin might therefore be of therapeutic significance in neurological diseases. Sixteen patients with different extrapyramidal disorders and seven patients with various EEG abnormalities were tested with 2-hour somatostatin infusions and control infusions with saline. Somatostatin did not induce any improvement or deterioration of symptoms, signs, or EEG abnormalities in any patient.
Authors:
E Dupont; A P Hansen; P Juul-Jensen; K Lundbaek; I Magnussen; B de Fine Olivarius
Related Documents :
16499766 - Absence of seizures despite high prevalence of epileptiform eeg abnormalities in childr...
2708516 - Clinical significance of periodic lateralized epileptiform discharges: relationship wit...
7333816 - A longitudinal electroencephalographic study in acute leukaemia.
20102536 - Attenuated asymmetry of functional connectivity in schizophrenia: a high-resolution eeg...
2679046 - Gastric varices: profile, classification, and management.
7895396 - Patient's preference regarding the option of performing unselective liver biopsy follow...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Acta neurologica Scandinavica     Volume:  57     ISSN:  0001-6314     ISO Abbreviation:  Acta Neurol. Scand.     Publication Date:  1978 Jun 
Date Detail:
Created Date:  1978-11-29     Completed Date:  1978-11-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370336     Medline TA:  Acta Neurol Scand     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  488-93     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Basal Ganglia Diseases / drug therapy*
Brain Neoplasms / complications
Clinical Trials as Topic
Double-Blind Method
Drug Evaluation
Dystonia Musculorum Deformans / drug therapy
Epilepsy / drug therapy*
Female
Humans
Huntington Disease / drug therapy
Male
Middle Aged
Myoclonus / drug therapy
Parkinson Disease / drug therapy
Somatostatin / therapeutic use*
Vascular Headaches / drug therapy
Chemical
Reg. No./Substance:
51110-01-1/Somatostatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The ejector flowmeter: an evaluation of its accuracy.
Next Document:  Ovarian biopsy in the evaluation of amenorrhea.